EVENTS · AMGN
PEERS
EARNINGS
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc. Common Stock is widely followed by market participants for its role in the biotechnology sector and its exposure to branded medicines, biologics, and specialty treatment areas.
Amgen raised its full year revenue forecast after third quarter sales and profit topped expectations
| Series | 1W | 1M |
|---|---|---|
| AMGN | +5.9% | +18.8% |
| Peers | +6.9% | +13.7% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 57 | 87 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 5.74 | 6.45 | +12.37% | — |
| Q2 FY2026 | 5.73 | 6.29 | +9.81% | +7.64% |
| Q1 FY2026 | 4.85 | 5.15 | +6.14% | −2.43% |
| Q4 FY2025 | 4.83 | 5.29 | +9.56% | +6.24% |
| Q3 FY2025 | 5.11 | 5.64 | +10.28% | +7.95% |
| Series | 1W | 1M |
|---|---|---|
| AMGN | +5.9% | +18.8% |
| Peers | +6.9% | +13.7% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 57 | 87 |
